Halozyme Therapeutics, Inc. (HALO) stock analysis

P/E above its 5-year median

Halozyme Therapeutics's P/E of 25.3 is above its own 5-year median of 19.1.

P/E above the industry

Halozyme Therapeutics's P/E of 25.3 is above the Drugs median of 25.0.

EV/EBITDA above its 5-year median

Halozyme Therapeutics's EV/EBITDA of 19.7 is above its 5-year median of 19.6.

P/S above the industry

Halozyme Therapeutics's price-to-sales of 6.31 is above the Drugs median of 4.73 (book value is negative, so we use sales).

Trading above fair value

The share price of $100.27 is above our fair value estimate of $83.32.

Margin of safety under 20%

The price is 20.3% above fair value, so there is no margin of safety.

Revenue growing 10%+ a year

Revenue grew 28.4% a year over the last three fiscal years.

EPS growing 10%+ a year

Diluted EPS grew 21.1% a year over the last three fiscal years.

Earnings growth not accelerating

Net income grew -18.5% over the last twelve months, against a 5-year average of 19.7% a year.

Growing faster than the industry

Revenue grew 45.0% over the last twelve months; the Drugs median is 7.7%.

Guidance raised

Halozyme Therapeutics raised its full year 2026 Non-GAAP diluted earnings per share outlook on Nov 5, 2026.

Gross margin slipping

Gross margin was 82.3% over the last twelve months, against 84.5% a year earlier.

Return on equity over 15%

Return on equity was 216% over the last twelve months and averaged 183% over five years.

Return on capital over 10%

Return on invested capital was 26.6%, above the 10% that usually covers the cost of capital.

Return on equity above the industry

Halozyme Therapeutics's return on equity of 216% is above the Drugs median of -57.0%.

Earnings grew over 5 years

Net income grew 19.7% a year on average over the last five fiscal years.

Net margin below its 5-year average

Net margin was 26.9% over the last twelve months, against a 5-year average of 44.4%.

Net margin above the industry

Halozyme Therapeutics's net margin of 26.9% is above the Drugs median of -53.5%.

Debt level

Needs debt and equity figures.

Debt trend

Needs a balance sheet from five years ago with positive equity.

Debt covered by cash flow

Operating cash flow over the last twelve months equals 27.6% of total debt.

Interest well covered

Operating income covers interest expense 30.6 times.

Short-term assets cover short-term debts

Current assets are 3.88 times current liabilities.

Low bankruptcy risk

The Altman Z-score is 3.54; above 3 is the safe zone and below 1.8 the distress zone.

No dividend

Halozyme Therapeutics has not paid a dividend in the last twelve months.

Yield against Treasuries

No dividend.

Yield against the market

No dividend.

Dividend stability

No dividend.

Earnings cover

No dividend.

Cash-flow cover

No dividend.